scholarly journals Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of angina pectoris of coronary heart disease (CHD)

Medicine ◽  
2021 ◽  
Vol 100 (52) ◽  
pp. e28450
Author(s):  
Shuang Wang ◽  
Ai Dong Liu ◽  
Zhilei Wang ◽  
Yue Zhang
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Efficacy And Safety ◽  
Chinese Herbal

scholarly journals Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of angina pectoris of coronary heart disease: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Shuang Wang ◽  
◽  
Aidong Liu ◽  
Zhilei Wang ◽  
Yue Zhang
Keyword(s):  
Systematic Review ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
Efficacy And Safety ◽  
Chinese Herbal

Review question / Objective: This study is the protocol for a systematic review to evaluate the Efficacy and safety of acupuncture combined with Chinese herbal medicine in the treatment of angina pectoris of coronary heart disease: a systematic review and meta-analysis. we conducted a systematic review and meta-analysis of published randomized clinical trials (RCTs) of such combined therapy in the treatment of angina pectoris of coronary heart disease, It provides a reliable scientific basis for clinicians to use this approach to treat angina pectoris of coronary heart disease. Information sources: We conducted a systematic search for relevant documents in the Chinese and English databases, and the search time is limited to November 23, 2021. The following eight databases are included : PubMed,EMBASE, Web of Science, The Cochrane Library, Chinese Biomedical Literature Database (CBM), Chinese National Knowledge Infrastructure (CNKI), Chinese Science and Technology Periodical Database (VIP), Wanfang Database.Relevant journals were searched to trace the references included in the study. Other resources will be searched if necessary.

scholarly journals Outcome Measures of Chinese Herbal Medicine for Coronary Heart Disease: An Overview of Systematic Reviews

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Jing Luo ◽  
Hao Xu
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Herbal Medicine ◽  
Outcome Measures ◽  
Systematic Reviews ◽  
Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Primary Endpoints

Objective. The aim of this overview was to summarize the outcome measures of Chinese herbal medicine (CHM) as the treatment of coronary heart disease (CHD) based on available systematic reviews (SRs), so as to display the current situation and evaluate the potential benefits and advantages of CHM on CHD.Methods. An extensive search included the Cochrane Database of Systematic Reviews, MEDLINE, and 4 databases in Chinese. SRs of CHM for CHD were included. Besides evaluating and summarizing the outcome measures, we also estimated the quality of the included reviews by PRISMA (preferred reporting items for systematic reviews and meta-analyses). Data were extracted according to predefined inclusion criteria by two independent reviewers.Results. 46 articles were included. 20 kinds of CHM were reviewed. 7 SRs were concerned with myocardial infarction (MI), 38 SRs were related to angina pectoris. 11 SRs had primary endpoints, while others focused on secondary endpoints to evaluate CHM for CHD such as angina pectoris and electrocardiogram (ECG). One SR reported more adverse effects of CHM for CHD and of the SRs analyzed quality of life. Many CHM appeared to have significant effect on improving symptoms, ECG, biomarkers and so on. However, most SRs failed to make a definite conclusion for the effectiveness of CHM in CHD patients due specifically to the poor evidence. And according to PRISMA we found most of the trials in the SRs were of low quality.Conclusion. Primary endpoints were not used widely. The benefits of CHM for CHD need to be confirmed in the future with RCTs of more persuasive primary endpoints and high-quality SRs.

Efficacy and safety of Chinese herbal medicine Guanxinshutong capsule for the treatment of chronic heart failure with ejection fraction decrease (<50%) caused by coronary heart disease: study protocol for a randomized controlled trial

2020 ◽  
Author(s):  
Yu Wang ◽  
Jiaping Xu ◽  
Jie-hong Yang ◽  
Ling Zhang ◽  
Yuan-jiang Pan ◽  
...  
Keyword(s):  
Heart Failure ◽  
Clinical Trial ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Chronic Heart Failure ◽  
Herbal Medicine ◽  
Ejection Fraction ◽  
Intervention Group ◽  
Efficacy And Safety ◽  
Chinese Herbal

Abstract Background Chronic Heart failure (CHF) is a global epidemic and common cardiovascular disease with high mortality and poor prognosis, which bring heavy burdens to society and family. Traditional Chinese medicine (TCM) has been extensively used in China as an adjunct treatment for CHF. Guanxinshutong capsule (GXST), approved by the China Food and Drug Administration (CFDA) in 2002 (No. Z20020055), is commonly used Chinese herbal medicine (CHM) for the treatment of coronary heart disease (CHD) currently. Both experimental research and small-sample clinical trials have shown that GXST could attenuate CHF. However, the effects of GXST on CHF as an adjunct therapy are lack of high-quality clinical evidence. This study is a large-scale, multi-center, double-blinded clinical trial to explore the efficacy and safety of GXST in CHF with ejection fraction decrease (<50%) caused by CHD. Methods This study is a multi-center, randomized, double-blind, placebo-controlled clinical trial. After 1week baseline period, a total of 480 participants will be randomly assigned to the intervention group and placebo group in ratio 2:1. Based on routine medications, the intervention group will be treated with GXST while the control group will be treated with placebo (both 0.3g/capsule, op, 3 capsules/time, thrice daily) for 12 weeks, and then be followed-up for another 40 weeks. The primary outcome is the effect of 6 min walk test (6MWT). The secondary outcomes include NT-proBNP, classification of the New York Heart Association (NYHA) heart function, Minnesota heart failure quality of life scale (MLHFQ), echocardiographic parameters, blood stasis syndrome symptom scale and clinical endpoint events. Metabolomics and proteomics will also be assessed. Adverse events (AEs) will be monitored throughout the trial. All the data will be recorded in electronic case report forms (eCRF) system database and analyzed in accordance with a predefined statistical analysis plan. Ethical approval of this trial has been granted by the Research Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese Medical University (ID: 2019-Y-003-02). Written informed consent of patients will be required. The results will be disseminated to the public through peer-reviewed journals and academic conferences. Discussion This study integrates the advantages of TCM and western medicine in the treatment of CHF, the result of this study will offer the efficacy and safety evidence of GXST on CHF with ejection fraction decrease (<50%).

scholarly journals An Overview of Systematic Reviews of Chinese Herbal Medicine for Alzheimer’s Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Nanyang Liu ◽  
Tingting Zhang ◽  
Jiahui Sun ◽  
Jiuxiu Yao ◽  
Lina Ma ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Herbal Medicine ◽  
Systematic Reviews ◽  
Chinese Herbal Medicine ◽  
Methodological Quality ◽  
Efficacy And Safety ◽  
Quality Of Evidence ◽  
Chinese Herbal

Background: Multiple systematic reviews (SRs) have been conducted to evaluate the efficacy and safety of Chinese herbal medicine (CHM) in patients with Alzheimer’s disease (AD). Here, we aim to perform an overview to assess the methodological quality and quality of evidence of the SRs to provide convincing data on the treatment of AD with CHM.Method: Six electronic databases including Chinese and English were searched, until April 31, 2021. Two researchers independently screen documents and extract data according to the predesigned rules. A Measure Tool to Assessment System Reviews 2 (AMSTAR-2) was used to investigate the methodological quality, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was used to determine the quality of evidence for outcomes.Results: Twelve qualified SRs including 163 randomized controlled trials were reviewed. The methodological quality of the included SRs was considered extremely low assessed through AMSTAR-2. Compared with western medicines (WM) alone, CHM as an adjuvant treatment has shown significant effects in improving Mini-mental State Examination, Alzheimer’s Disease Assessment Scale-Cognitive, and Clinical Dementia Rating scores. The same is true for CHM alone. Regarding the effect on Activities Daily Living, neither the single CHM nor the combination with WM has an obvious effect. For the total effective rate, both single CHM and the combination with WM shown significant effects. Nine SRs suggested that CHM as adjuvant therapy or single-use had fewer adverse events than WM. Additionally, the quality of evidence for the main outcome was reviewed as low or extremely low according to GRADE profiler data.Conclusion: Current evidence suggests that CHM may be beneficial in improving the cognitive function of AD patients. However, we should be cautious about the evidence due to methodological flaws and low quality. High-quality RCTs are further needed to confirm the efficacy and safety of CHM for AD.

Sign in / Sign up

Export Citation Format

Share Document